

References

I-33

1. Collins C, Dall'Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSERVE study in the USA. *Lupus Sci Med*. 2016;3(1).
2. Ke X, Eisenberg Lawrence D, Oglesby A, et al. A retrospective administrative claims database evaluation of the utilization of belimumab in US managed care settings. *Clin Ther*. 2015;37(12):2852-63.
3. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: Safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
4. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
5. MICROMEDEX DrugDex Compendium © 2020. Belimumab (Benlysta).
6. Clinical Pharmacology™ Compendia. 2020. Tampa FL: Gold Standard, Inc. Belimumab.
7. Belimumab (Benlysta) for injection [package insert]. Human Genome Sciences, Inc. Rockville, MD. Revised 03/2021.
8. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two week randomized, double-blind, placebo-controlled study. *Arthritis Rheumatol*. 2017;69(5):1016–1027.
9. Bangert E, Wakani L, Merchant M, et al. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. *Patient Relat Outcome Meas*. 2019;10:1-7.
10. Furie, R., Rovin, B. H., Houssiau, et.al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. *New England Journal of Medicine*. 2020. 383(12);1117-1128.
11. Parodis I, Johansson P, Gomez A, et. al. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. *Rheumatology*. 2019;58(12):2170-2176.
12. Wallace DJ, Petri M, Fettiplace J, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients With systemic lupus erythematosus. *Arthritis & Rheumatology*. 2019;71(7):1125-1134.